Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Glaucoma Pipeline Therapeutics Report 2016: Pipeline Review of 59 Companies & 102 Drug Molecules - Research and Markets

Research and Markets
Posted on: 24 Oct 16

Research and Markets has announced the addition of the "Glaucoma - Pipeline Review, H2 2016" report to their offering.

Glaucoma pipeline therapeutics constitutes close to 116 molecules, out of which approximately 102 molecules are developed by Companies and the remaining by the Universities/Institutes. Our latest report Glaucoma - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, or family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye. The molecules developed by Companies in Pre-Registration, Filing Rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 9, 23, 9, 45, 11 and 1, respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 7, 6 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Glaucoma Overview
  3. Therapeutics Development
  4. Pipeline Products for Glaucoma - Overview
  5. Pipeline Products for Glaucoma - Comparative Analysis
  6. Glaucoma - Therapeutics under Development by Companies
  7. Glaucoma - Therapeutics under Investigation by Universities/Institutes
  8. Glaucoma Products Glance
  9. Late-Stage Products
  10. Clinical-Stage Products
  11. Early-Stage Products
  12. Glaucoma - Products under Development by Companies
  13. Glaucoma - Products under Investigation by Universities/Institutes
  14. Glaucoma - Companies Involved in Therapeutics Development
  • AC Immune SA
  • Allergan Plc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bausch & Lomb Incorporated
  • BioAxone BioSciences Inc.
  • Bionure Farma S.L.
  • Coronis Partners Ltd.
  • D. Western Therapeutics Institute Inc.
  • Dompe Farmaceutici S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Glaukos Corporation
  • Graybug Vision Inc.
  • Handok Inc.
  • HitGen Ltd.
  • Kukje Pharmaceutical Industry Co. Ltd.
  • Laboratoires Thea S.A.
  • Laboratorios Sophia S.A. de C.V.
  • Lee's Pharmaceutical Holdings Limited
  • Lexicon Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Novaliq GmbH
  • Ocular Therapeutix Inc.
  • Oculis ehf
  • Ohr Pharmaceutical Inc.
  • Otsuka Holdings Co. Ltd.
  • pSivida Corp.
  • Quark Pharmaceuticals Inc.
  • Quethera Limited
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Santen Pharmaceutical Co. Ltd.
  • Senju Pharmaceutical Co. Ltd.
  • Shire Plc

For more information about this report visit

View source version on

Business Wire

Last updated on: 24/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.